Many groups have identified potential targets to enhance the cytotoxic effects of cancer therapeutics such as paclitaxel in lung cancer, PARP inhibitors in breast cancer, HDAC inhibitors in osteosarcoma, imatinib in CML, and BRAF inhibitors in colon cancer and melanoma among others [30–37]. This evidence concerns the gene BRAF and cancer.